Home  /  Resource Library  /  Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenstroms Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study

Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenstroms Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study

Results of a phase III study examining ibrutinib combined with rituximab for treatment of Waldenstrom’s macroglobulinemia.